You are here: Home: CACU 1 | 2007: Faculty Disclosures
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-
the-art education. We assess potential conflicts of interest with faculty, planners and managers of
CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
validation process. The content of each activity is reviewed by both a member of the scientific staff
and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and
review of content for educational activities and report the following real or apparent conflicts of
interest for themselves (or their spouses/partners) that have been resolved through a peer review
process: John H Brebner, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD,
Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel,
PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder
of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from
Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/
Onyx Pharmaceuticals Inc, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc,
Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our
educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
of interest that have been resolved through a peer review process:
Dr Mackey — Honoraria: Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Roche
Laboratories Inc, Sanofi-Aventis. Dr Ravdin — Consulting Fees: AstraZeneca Pharmaceuticals LP, Sanofi-Aventis;
Ownership Interest: Adjuvant Inc. Dr Hudis — Consulting Fees: Amgen Inc, Novartis Pharmaceuticals Corporation,
Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis; Fees for Non-CME Services Received Directly from Commercial
Interest or Their Agents: AstraZeneca Pharmaceuticals LP, Genentech BioOncology; Ownership Interest: Genomic
Health Inc.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
|
